Here you will find all the news about our studies and the follow-up reports from ABCSG events

Paradigm shift: a changing CDK4/6 inhibitor treatment landscape

The on-demand video of the webinar “Paradigm shift: a changing CDK4/6 inhibitor treatment landscape” is now online!


The virtual continuing education event “Paradigm shift: a changing CDK4/6 inhibitor treatment landscape” took place on Thursday, September 14th , 2023 (06:00 – 08:00 pm, CET). A total of 87 participants from 13 countries took part in the webinar.

read more
ABCSG-Präsident Prof. Michael Gnant zählt 2022 erneut zum Who is Who der globalen akademischen Forschungselite

ABCSG President Prof. Michael Gnant in 2022 once again among the who’s who of the global academic research elite


For the third time already, Austria’s internationally renowned cancer researcher Professor Michael Gnant, MD, FACS, FEBS has been named as one of the worldwide “Highly Cited Researchers 2022”.

read more
Univ. Prof. Dr. Michael Gnant

The Positive Impact of Disclosing “Negative” Research Results


For the Austrian Breast and Colorectal Cancer Study Group (ABCSG), the year 2021 showed how successful and thriving – and at times challenging – clinical research can be. From practice-changing study results to the positive impact and opportunities of disclosing negative trial outcome, Professor Michael Gnant, President of the ABCSG, provides insight into some ABCSG […]

read more

PALLAS 1st Call for Research Project Proposals – 15. Sep. 2021- 15. Jän. 2022


The first full scientific publication of PALLAS study data was made public in 2020 and subsequent publications are in preparations.

read more

First results of ABCSG 51 / AURORA study published


The AURORA program is dedicated to researching the molecular characteristics of locally recurrent / advanced and metastatic breast cancer not amenable to treatment with curative intent. For this purpose, the tumor and blood samples of participants are assessed for tumor heterogeneity, clonal evolution and transcriptional changes using high-throughput sequencing technologies (NGS). In addition, biomarkers of […]

read more

Share on